- Home
- GNW vs HCM Comparison
GNW vs HCM Comparison
Compare GNW & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | HCM |
|---|---|---|
| Founded | 1871 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.6B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNW | HCM |
|---|---|---|
| Price | $8.96 | $13.41 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 1 | 1 |
| Target Price | $10.50 | ★ $13.75 |
| AVG Volume (30 Days) | ★ 2.5M | 28.6K |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $7,301,000,000.00 | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | $16.64 | ★ $5.49 |
| Revenue Growth | ★ 0.08 | N/A |
| 52 Week Low | $6.63 | $13.06 |
| 52 Week High | $9.28 | $19.50 |
Technical Indicators
Market Signals| Indicator | GNW | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 63.21 | 34.83 |
| Support Level | $7.97 | $13.08 |
| Resistance Level | $9.20 | $15.59 |
| Average True Range (ATR) | 0.16 | 0.42 |
| MACD | 0.02 | -0.23 |
| Stochastic Oscillator | 75.37 | 9.34 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.